Recently, Nanjing King-Friend Biochemical Pharmaceutical Co., LTD. (hereinafter referred to as "King-Friend") received an approval letter from the U.S. Food and Drug Administration (hereinafter referred to as "FDA") for its liraglutide Injection, allowing it to be marketed and sold.

Liraglutide Injection can be used as an auxiliary means of diet and exercise to improve blood sugar control in adults and children aged 10 and above with type 2 diabetes. Reduce the risk of major adverse cardiovascular events in adult patients with type 2 diabetes mellitus accompanied by cardiovascular diseases.

Liraglutide Injection will be launched in the United States in the near future, benefiting more patients around the world.